Clicks Group Limited Overview
Clicks Group is South Africa's dominant retail-led healthcare platform. It combines the country's largest retail pharmacy chain (Clicks: 999 stores and 797 dispensaries at February 2026) with its leading full-range pharmaceutical wholesaler, United Pharmaceutical Distributors (UPD). The model is vertically integrated. Clicks buys about 98% of its pharmaceutical needs from UPD. UPD in turn supplies private hospital groups and independent pharmacies, and provides pre-wholesale "bulk" distribution for drug manufacturers. Front-shop health, beauty and personal care categories, where Clicks holds leading NielsenIQ shares (43.1% in skincare), are monetised through a 12.9-million-member ClubCard programme that drives about 84% of sales. Growing private label adds further margin, at 26.5% of sales. The group has historically delivered 40–50% returns on equity with no interest-bearing debt. That record earned it a long-standing premium valuation. In 2026 the stock de-rated sharply as earnings growth slowed to a guided 4–9%, rivals (Dis-Chem and Shoprite's Medirite) intensified their offers, and a warehouse-system disruption exposed execution risk.
Company's own description (paraphrased from the FY2025 results and integrated report, S1/S6)
The group describes itself as a leader in healthcare. It frames its purpose around widening access to affordable healthcare for South Africans. It presents Clicks as the country's leading health, wellness and beauty retailer and its foremost pharmacy chain: an expanding network of over 990 stores and 780 pharmacies at FY2025 year-end, supported by a growing digital presence. It presents UPD as the country's leading full-range pharmaceutical wholesaler, which provides the distribution capability for the group's healthcare strategy. The 2025 sustainability report adds that the group runs "vertically integrated operations". Its brand portfolio includes exclusive franchises (The Body Shop), owned brands (Sorbet) and private labels (for example MyEarth).
Independent characterisation
Clicks Group is best understood as three interlocking economic engines.
-
A high-frequency convenience health and beauty retailer (Clicks front shop). This engine earns most group profit. Front-shop health, beauty and personal care, and general merchandise (including small electrical appliances) together made up about 73% of FY2025 retail turnover. Margins come from private label, exclusive brands, promotional intensity (47.8% of turnover sold on promotion in H1 FY2026) and supplier-funded "other income" (advertising and cost recoveries). Retail other income rose 17% to R2.20bn in FY2025.
-
A regulated retail pharmacy chain. Dispensary sales were R10.06bn (26.8% of retail turnover excluding Unicorn) in FY2025. Medicine prices are regulated through the Single Exit Price (SEP) and a capped dispensing fee. This means pharmacy is a footfall and loyalty driver rather than a high-margin line. The binding growth constraint is the Department of Health's licensing of new dispensaries. In H1 FY2026, 105 stores still had no dispensary.
-
A pharmaceutical wholesaler and logistics provider (UPD). UPD earned R18.7bn of FY2025 segment turnover at a 3.3% trading margin. It also manages notional turnover for bulk-distribution clients that is not booked as revenue: total managed turnover was R30.5bn in FY2025. UPD gives Clicks supply security and purchasing scale, and earns fees from manufacturers.
Revenue model and mix
Product sales: (goods sold to customers): R47.83bn turnover in FY2025, which is 93% of IFRS revenue of R51.43bn.
Service and fee income: (booked as "other income"): R3.46bn in FY2025. This comprises distribution and logistics fees of R1.45bn (UPD bulk and agency services) and cost recoveries and other income of R2.01bn (supplier advertising, promotional recoveries, Sorbet franchise fees and similar).
Franchise and licensing income: Sorbet franchise fees from about 190 franchised salons (amount not separately disclosed). The Body Shop is operated under licence, so it is a cost to Clicks rather than income.
Subscription or SaaS: the LEAP pharmacy management system (developed by 180 Degrees) is being marketed to third-party pharmacies. Revenue is not separately disclosed.
Value-chain position, customers and end-markets
Upstream: Clicks sources from multinational and local fast-moving consumer goods and pharmaceutical manufacturers and from private-label contract manufacturers. Since the August 2024 Unicorn disposal it has had no pharmaceutical manufacturing.
Midstream: UPD's five owned distribution centres plus three Clicks retail distribution centres. The group reports that the Clicks distribution centres supply about 98.5% of the chain's product needs (S14 history page).
Downstream customers: mass and middle-income consumers (247–252 stores sit in low-income areas and contribute about 23.4–23.7% of retail turnover); medical-scheme and cash pharmacy patients; private hospital groups (36.2% of UPD fine-wholesale turnover in FY2025); about 1,020 independent pharmacies; and pharmaceutical principals (bulk distribution).
End-markets: South African retail pharmacy, front-shop health and OTC, beauty and personal care, baby, small electrical appliances, private-hospital pharmaceutical supply and pharma logistics. Cross-border operations cover Namibia, Botswana, Eswatini and Lesotho.
Operating KPIs (five-year)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total retail stores (number) | 841 | 898 | 950 | 1,002 | 1,060 |
| Clicks stores (number) | 781 | 837 | 881 | 930 | 985 |
| In-store pharmacies (number) | 621 | 673 | 711 | 720 | 780 |
| The Body Shop standalone stores (number) | 59 | 58 | 61 | 57 | 55 |
| Clicks Baby standalone stores (number) | 1 | 3 | 4 | 6 | 6 |
| Sorbet corporate stores (number) | 0 | 0 | 4 | 9 | 14 |
| Weighted retail trading area (thousand m2) | 384.8 | 397.1 | 425.4 | 448.3 | 474.5 |
| Weighted annual sales per m2 (ZAR) | 68,934 | 72,822 | 73,200 | 77,666 | 78,432 |
| Permanent employees (number) | 15,871 | 16,492 | 18,447 | 19,621 | 20,102 |
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| ClubCard active members (millions) | 9.7 | 10.4 | 11.8 | 12.6 |
| ClubCard cashback paid (ZAR m) | 601 | 689 | 780 | 855 |
| In-store clinics (number) | 199 | 203 | 206 | 225 |
Sources: S1 (FY2024–FY2025), S3 (FY2022–FY2023), S4 (FY2021–FY2022). FY2021 sales per m2 is for continuing operations. FY2025 Clicks stores include 1 UniCare store.
Sources: S4, S3, S13/S6 (FY2024), S1/S6 (FY2025). At H1 FY2026: 12.9m members, 83.7% of sales, R527m cashback in six months, 226 clinics.
Strategy
Stated strategy (themes paraphrased from FY2025/H1 FY2026 materials, S1, S2, S3)
The group frames Clicks' growth around four strategic pillars:
-
Value: price competitiveness, promotions, generics and ClubCard cashback.
-
Convenience: store and pharmacy rollout, clinics, online and new formats.
-
Differentiation: private label and exclusive brands, beauty halls, UniCare, Sorbet, ARC.
-
Personalisation: ClubCard data, personalised deals and the app.
These sit within six group strategic objectives:
-
expand store, pharmacy and online reach;
-
run an efficient centralised supply chain;
-
gain share in pharmacy and core front-shop categories;
-
build an inclusive, transformed organisation with a talent pipeline;
-
grow UPD's national wholesale and distribution share;
-
maintain efficient capital management and robust ESG practice.
Initiatives announced or advanced in the last 24 months
| Initiative | Detail | Status |
|---|---|---|
| Store and pharmacy rollout | 40–50 new stores and 40–50 pharmacies a year; medium-term target of 1,200 Clicks stores | 1,003 Clicks stores and 797 pharmacies at Feb 2026 |
| Differentiated concept stores | 10 pilot concept stores in H2 FY2026 | Announced April 2026 |
| Smaller and rural formats | Trialling smaller formats (FY2025); a new smaller rural store format was cited by Merchant West in Sep 2026 (M3) | Pilot |
| UniCare specialised pharmacies | 10–15 sites over the medium term; greenfield and acquisition-led | 3 UniCare 24/7 sites by May 2026 (M9); one further acquisition planned per S2 |
| ClubCard enhancements | Hyper-personalised deals; move to monthly cashback payments | Implemented in H1 FY2026 |
| LEAP pharmacy system | In all Clicks pharmacies; commercialised to third parties | Live |
| Omnichannel | R1.3–1.4bn a year of capex over the next three years, with continued investment in systems and omnichannel capability; smart pharmacy lockers pilot; medicine delivery being explored within regulation (M8) | Ongoing |
| Warehouse management system | Rollout to the Cape Town, Centurion and Durban DCs. Cape Town go-live disrupted the festive season; Durban is next (FY2026 capex). | Cape Town availability normalised by end Feb 2026 |
| UPD systems | SAP/WMS rolled out to seven distribution clients; remainder by March 2026 | Completed or completing |
| UPD medical consumables | Mr First Aid acquired (74%); offer launched | Integration complete |
| Green logistics | 42 EVs in Apr–May 2025; 43 more in Mar 2026 (85 total) | Live |
| Private-label expansion | 35% front-shop private-label target; 330 private-label medicines targeted for FY2026 | Ongoing |
| Cost and energy | Solar (5,563 MWh in FY2025), batteries and EVs reduce electricity and fuel costs | Ongoing |
| ESG | Carbon neutrality by 2050; 10% Scope 1+2 intensity reduction by 2030 (from FY2015 base); IFRS S1/S2 alignment | Ongoing |
Capital expenditure plan (FY2026, S1/S2)
Total R1,256m:
Stores: R662m for 40–50 new Clicks stores and pharmacies and 80–90 refurbishments (raised from 70–80 in October 2025).
Infrastructure: R594m, of which R88m is UPD IT and warehouse equipment and R506m is retail systems and infrastructure, including the WMS rollout to the Durban DC.
Medium-term financial targets
| Metric | Medium-term target | FY2023 achieved | FY2025 achieved |
|---|---|---|---|
| Return on equity (%) | 40–50 | 43.6 | 49.2 |
| ROIC excluding IFRS 16 (%) | 40–50 | 41.5 | 47.0 |
| ROIC (%) | 20–30 | 28.4 | 30.7 |
| Return on assets (%) | 11–15 | 13.8 | 14.9 |
| Net working capital days | 30–35 | 34 | 34 |
| Group trading margin (%) | 9.0–10.0 (8.0–9.0 in FY2023) | 8.7 | 9.8 |
| Retail trading margin (%) | 10.0–11.0 (9.0–10.0 in FY2023) | 10.0 | 10.5 |
| Distribution trading margin (%) | 2.8–3.3 | 2.8 | 3.3 |
| Dividend payout ratio (%) | 60–65 | 65 | 65 |
The margin targets were raised by 100 bps between the FY2023 and FY2025 presentations, reflecting structural margin gains. FY2025 ROIC of 30.7% marginally exceeded its 20–30% range.
FY2026 guidance: diluted HEPS growth of 4–9% over FY2025. The guidance assumes a constrained H2 retail environment, adverse effects of geopolitical conflict on the South African macro outlook (fuel prices after the Iran war), performance within medium-term targets, and no regulatory change.
Products & Services
Retail segment
| Offering | Description and capabilities | Target customer | Launch / latest | Pricing model | Flagship / key data |
|---|---|---|---|---|---|
| Clicks (store chain) | Health, beauty and wellness drugstore. Two formats: convenience (775 stores) and destination (230 stores), as at H1 FY2026. Total 1,005 stores, which includes 6 Clicks Baby standalone stores. | Mass to middle-income households; urban and peri-urban | Founded 1968; 1,000th store in H1 FY2026 | Everyday low price plus heavy promotions ("3 for 2"); price index vs four national rivals of 96.9–99.0 in FY2025 | 47.8% of H1 FY2026 turnover sold on promotion |
| Clicks Pharmacy (dispensary) | 797 in-store dispensaries (28 Feb 2026). Repeat prescription service covers 53% of repeat scripts (FY2025). LEAP pharmacy management system installed in all pharmacies. | Medical-scheme members and cash patients | First pharmacy 2004; 800th April 2026 | Regulated SEP plus dispensing fee | Generics 58% of pharmacy sales and 72.1% of volume (H1 FY2026); retail pharmacy share 24.9% (IQVIA) |
| Clicks clinics | 226 in-store primary healthcare clinics: immunisation, screening, family planning, wound and travel care; Clicks Helping Hand Trust provides free consultations (131,855 beneficiaries in FY2025) | Uninsured and insured patients | Ongoing | Fee per service; free via the Trust | Clicks Virtual Doctor telemedicine booths being rolled out |
| UniCare / UniCare 24/7 Trusted Health | Specialised 24-hour pharmacy format: multidisciplinary team, after-hours doctor, diabetes, travel, wound, orthopaedic and surgical support, IV infusions | Chronic, acute and after-hours patients | First format 2025; third site (Somerset West) opened May 2026 (M9). Builds on M-Kem (Bellville). | Dispensing plus service fees | Target of 10–15 specialised pharmacies over the medium term |
| Clicks Baby | 6 standalone stores plus about 14 store-in-stores (FY2025); "Made4Baby" and "Clicks Baby" ranges | Parents | First standalone store at Gateway (KZN) | Retail | Best Baby Retailer award (Baby YumYum Parent Choice) |
| Front-shop health | OTC medicines, vitamins and supplements, wellness | All | — | Retail | R9.63bn turnover in FY2025; front-shop health share 33.1% (NielsenIQ) |
| Beauty & personal care | Skincare, haircare, cosmetics, fragrance; "beauty halls" format | All, skewed female | Beauty halls rolled out from 2022–23 | Retail | Skincare share 43.8% (FY2025) and 43.1% (H1 FY2026) |
| General merchandise | Small electrical appliances, gifting, homeware, electronics | All | Elevation of men's grooming and electronics in H1 FY2026 | Retail | Small electrical appliance share 18.5% (H1 FY2026) |
| Private label & exclusive brands | R9.7bn sales in FY2025 (+10.7%). Brands include Clicks, MyEarth (eco-friendly household and personal care), Smudge (cosmetics), Sunprotect, Made4Baby, Clicks Baby, Sorbet products, and 314 private-label medicines (FY2025). | Value-seeking consumers | Ongoing; 330 medicines targeted for FY2026 | Retail (higher margin) | 26.5% of sales in H1 FY2026 (front shop 31.3%, pharmacy 12.6%); medium-term target of 35% of front-shop sales; six products won Product of the Year 2025 |
| The Body Shop (South Africa) | Exclusive franchise of the UK ethical beauty brand: 53 standalone stores (Feb 2026) plus presence in 257 Clicks stores | Middle and upper-income beauty buyers | Franchise since 2001; extended 2023; 10-year extension reported with Aurelius-owned TBS (late 2024) | Retail | "Workshop" store format being rolled out |
| Sorbet | Beauty salon franchise chain (about 192 franchised salons plus 17 corporate stores at Feb 2026) and Sorbet-branded products sold in Clicks | Beauty-service consumers | Acquired 1 Jun 2023 | Franchise fees plus corporate salon services and product sales | Salon turnover +7.8% in H1 FY2026; first store in Botswana; "Sorbet-Preneur" employee-franchise programme |
| ARC Stores | Beauty retail concept in the group's ecosystem. Opened Africa's largest beauty store at Sandton City (FY2025). Ownership and structure not detailed in sources reviewed. | Premium beauty | FY2025 | Retail | ARC customer spend in Clicks of R331m over 12 months (+20.9%) |
| ClubCard | Free loyalty programme: points converted to cashback (paid monthly since FY2026, S2); personalised "My ClubCard Deals"; access via app and WhatsApp | All Clicks shoppers | Launched 1995 | Cashback on spend | 12.9m active members; 83.7% of sales; voted 2nd-best loyalty programme in SA (2026 whitepaper) |
| Digital / omnichannel | Clicks app and website; Montague Gardens (Cape Town) e-commerce fulfilment warehouse (2,232 m2; up to 1.4m parcels a year); smart pharmacy lockers in pilot | Digital shoppers | Omnichannel warehouse c. 2024 | Retail | Online sales +15.9% (FY2025) and +17.9% (H1 FY2026); online plus "research online, purchase offline" at 4.1% of sales (FY2025) |
| LEAP pharmacy system (180 Degrees) | Pharmacy management software developed in-house after the 180 Degrees acquisition | Internal; third-party pharmacies | Rollout to all Clicks pharmacies by Nov 2025 | Licensing (terms not disclosed) | Expected R40–50m a year of cost savings and revenue over a 3-year rollout |
Distribution segment (UPD)
| Offering | Description | Customers | Key data |
|---|---|---|---|
| Fine wholesale | Full-range pharmaceutical wholesale | Clicks (58.4% of FY2025 fine wholesale), private hospitals (36.2%), independent pharmacies and other (5.4%) | R13.89bn in FY2025 (+5.2%); wholesale market share 26.2% (FY2025) and 25.7% (Feb 2026, IQVIA) |
| Bulk / agency distribution | Pre-wholesale logistics for manufacturers. Revenue is booked as turnover for preferred-supplier contracts and as fees for agency contracts. | Pharmaceutical principals (25 bulk clients in FY2024) | Bulk wholesale R4.77bn in FY2025; preferred-supplier bulk +31.1% in H1 FY2026; two contracts lost in Q4 FY2025 |
| Medical consumables (Mr First Aid) | 74% acquired on 31 Oct 2025; offer launched to customers in H2 FY2026 | Hospitals, pharmacies, corporate | Purchase price R26.6m |
| Green logistics | 85 pharma-compliant EVs (H1 FY2026); 86% of wholesale deliveries no longer exposed to fuel costs | — | Supports cost containment |
Total UPD managed turnover (wholesale plus notional bulk): R30.6bn (FY2022), R32.1bn (FY2023), R29.9bn (FY2024), R30.5bn (FY2025), and R14.1bn in H1 FY2026, down 0.2%.
Brands exited
Musica: closed in FY2021 (discontinued operation, S4).
Claire's: listed as a franchise brand in the September 2021 trading update; absent from FY2022 commentary, which names only GNC and The Body Shop.
GNC: named in FY2024 retail scope but no longer named in FY2025 or FY2026 retail definitions. Exit terms are not publicly disclosed in sources reviewed.
Unicorn Pharmaceuticals: divested on 1 August 2024.
Financial Narrative
Income statement
Sources: S1 (FY2024–FY2025), S3 (FY2022–FY2023), S4 (FY2021). EBITDA is derived as reported trading profit plus total D&A from the cash-flow note, on an IFRS 16 basis that includes right-of-use depreciation. FY2021 profit includes a R76.2m loss from discontinued Musica. Continuing FY2021 diluted HEPS was 793.7c. FY2022 includes R325.9m of insurance proceeds in other income. Adjusted diluted HEPS was 836.8c (FY2021) and 936.6c (FY2022).
Margins and growth
Sources: S1, S3, S4. FY2021 dHEPS growth is derived from the company's 10-year chart (774c vs 754c in FY2020).
Compound annual growth rates, FY2021–FY2025 (derived): turnover 6.4%; diluted HEPS 15.2% (inflated by the depressed FY2021 base; the company's own 10-year dHEPS CAGR to FY2025 is 13.5%, S1); DPS 16.0%.
Commentary on income-statement trends. The defining feature of the five years is margin expansion far ahead of sales growth. Turnover compounded at only 6.4% a year. Gross margin, however, rose 430 bps, from 19.5% to 23.8%. The drivers were:
-
mix shift toward retail (from 70.5% to 78.5% of group turnover);
-
private-label penetration (24.2% to 25.9% of Clicks sales between FY2022 and FY2025);
-
the recovery of higher-margin beauty after Covid;
-
the end of low-margin vaccinations (R1.1bn of turnover in FY2022 vs R4m in FY2023).
Other income grew faster than turnover in every year after FY2022 (+12.3% in FY2025), as supplier-funded marketing and cost recoveries scaled with ClubCard data monetisation. The trading margin consequently rose 160 bps on an adjusted basis, from 8.2% to 9.8%.
Inflections.
FY2023: UPD's ERP/WMS implementation, load-shedding diesel costs (R53.8m) and a low SEP increase cut distribution profit by 18.3%. Reported dHEPS growth fell to 1.1%; adjusted growth was 11.5%.
FY2024: Retail turnover rose 11.7% despite the pharmacy licence freeze, and dHEPS grew 14.3%.
FY2025: Growth decelerated to 5.3% as selling-price inflation fell to 2.1% and the Unicorn turnover base dropped out. Earnings still grew 14.1% through margin, cost control (distribution costs +1.9%) and buybacks.
H1 FY2026: The model's dependence on margin expansion became visible. Total income margin fell 30 bps and the trading margin was flat at 9.1%. Headline earnings grew only 6.4%, and buybacks lifted per-share growth to 8.1%.
Balance sheet
Sources: S1, S3, S4. The balance sheets show no bank borrowings in any year; the only interest-bearing obligations are IFRS 16 lease liabilities. Net debt including leases is derived as total lease liabilities less cash. It reconciles to the company's "interest-bearing debt including cash to shareholders' interest" ratio (11.5% in FY2025).
Interim balance sheet (28 Feb 2026, S2): total assets R23.00bn; cash R1.24bn (seasonally low after the January final dividend and R752m of buybacks); total lease liabilities R4.41bn; equity R6.10bn; inventories R9.03bn (+13.4% year on year, partly because of the WMS disruption); goodwill R240.4m (Mr First Aid added); a non-controlling interest of R7.0m arose for the first time.
Cash flow
Sources: S1, S3, S4. Free cash flow is derived as operating cash flow before dividends less total capex. The post-lease measure also deducts lease principal repayments.
Commentary. Cash conversion is strong and structural. The retail engine is funded by supplier credit: creditor days of 64 in FY2025 against 77 inventory days and 5 debtor days. Post-lease free cash flow covered dividends in every year except FY2022, when working capital normalised after the civil unrest because creditor terms extended in 2021 unwound. The group has returned R22.3bn to shareholders since 2006: R14.5bn in dividends and R7.8bn in buybacks at an average price of R47.33 a share. The company says the repurchased shares were worth R61.2bn at the FY2025 year-end. In H1 FY2026, net operating cash flow after dividends was negative R465.8m, which is seasonal. R2.27bn was returned in six months, R752m of it via buybacks.
Ratios
Sources: S1, S3, S4: Sources: S1, S3, S4 (medium-term target slides).
Commentary on returns and balance-sheet strength. ROE near 50% is a product of genuine economic returns (ROIC of 47% excluding IFRS 16) amplified by a deliberately lean equity base, sustained through a 65% payout plus buybacks. It is not leverage: there are no bank borrowings. The chief balance-sheet risk is working capital rather than debt. Inventory days have drifted up from 66 to 78 (and to 89 at the February 2026 half-year). The causes are new-store fills, availability-led stocking, GLP-1 buy-ins at UPD and the Cape Town WMS disruption. If that drift persists, it would dilute cash conversion. Interest cover fell in FY2024 because lease finance costs rose with network expansion (retail lease finance cost R338m in FY2025, +20.9%), not because of any borrowing.
Interim snapshot (H1 FY2025 vs H1 FY2026)
Source: S2.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Retail turnover (ZAR Mn) | 26,329.1 | 29,405.1 | 31,724.9 | 35,438.5 | 37,554.5 |
Distribution turnover (ZAR Mn) | 17,378.2 | 16,922.3 | 17,175.3 | 17,749.6 | 18,658.1 |
Intragroup elimination (ZAR Mn) | -6,368.3 | -6,740.3 | -7,278.5 | -7,750.5 | -8,384.5 |
Group turnover (ZAR Mn) | 37,339.0 | 39,587.1 | 41,621.7 | 45,437.6 | 47,828.1 |
Retail turnover growth (%) | 8.3 | 11.7 | 7.9 | 11.7 | 6.0 |
Distribution turnover growth (%) | 12.3 | -2.6 | 1.5 | 3.3 | 5.1 |
Retail share of group turnover (%) | 70.5 | 74.3 | 76.2 | 78.0 | 78.5 |
Distribution external share of group turnover (%) | 29.5 | 25.7 | 23.8 | 22.0 | 21.5 |
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Retail trading profit (ZAR Mn) | 2,398.3 | 3,060.4 | 3,159.1 | 3,628.1 | 3,931.4 |
Distribution trading profit (ZAR Mn) | 532.5 | 596.9 | 487.5 | 573.4 | 624.9 |
Intragroup trading profit (ZAR Mn) | -33.9 | -6.9 | -23.6 | -29.7 | 122.3 |
Retail trading margin (%) | 9.1 | 10.4 | 10.0 | 10.2 | 10.5 |
Distribution trading margin (%) | 3.1 | 3.5 | 2.8 | 3.2 | 3.3 |
Retail trading profit growth (%) | 4.0 | 27.6 | 3.2 | 14.8 | 8.4 |
Distribution trading profit growth (%) | 3.8 | 12.1 | -18.3 | 17.6 | 9.0 |
Revenue by Segment and Segment Margins & Growth (%) (Half-Yearly)
| Metric | H1 FY2025 | H1 FY2026 |
|---|---|---|
Retail turnover (ZAR Mn) | 18,384.3 | 19,372.8 |
Distribution turnover (ZAR Mn) | 8,771.2 | 9,908.0 |
Intragroup elimination (ZAR Mn) | -3,991.3 | -4,408.6 |
Retail trading profit (ZAR Mn) | 1,802.3 | 2,000.4 |
Distribution trading profit (ZAR Mn) | 227.3 | 243.2 |
Retail trading margin (%) | 9.8 | 10.3 |
Distribution trading margin (%) | 2.6 | 2.5 |
Revenue by Segment
| Metric | FY2024 | FY2025 |
|---|---|---|
Pharmacy turnover (ZAR Mn) | 9,745.7 | 10,058.6 |
Front shop health turnover (ZAR Mn) | 8,951.8 | 9,625.4 |
Beauty and personal care turnover (ZAR Mn) | 11,369.4 | 12,202.1 |
General merchandise turnover (ZAR Mn) | 5,371.6 | 5,668.4 |
Total retail turnover (ZAR Mn) | 35,438.5 | 37,554.5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (Half-Yearly)
| Metric | H1 FY2025 | H1 FY2026 |
|---|---|---|
Pharmacy turnover (ZAR Mn) | 4,713.1 | 5,116.3 |
Front shop health turnover (ZAR Mn) | 4,646.5 | 4,789.6 |
Beauty and personal care turnover (ZAR Mn) | 6,188.4 | 6,547.2 |
General merchandise turnover (ZAR Mn) | 2,836.2 | 2,919.8 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Turnover (ZAR Mn) | 37,339.0 | 39,587.1 | 41,621.7 | 45,437.6 | 47,828.1 |
IFRS revenue incl. other and financial income (ZAR Mn) | 39,982.4 | 42,500.0 | 44,560.5 | 48,609.8 | 51,427.0 |
Gross profit (ZAR Mn) | 7,272.0 | 8,432.3 | 9,313.9 | 10,632.4 | 11,399.7 |
Other income incl. insurance proceeds (ZAR Mn) | 2,609.2 | 2,867.4 | 2,846.6 | 3,082.3 | 3,461.2 |
Total income (ZAR Mn) | 9,881.2 | 11,299.7 | 12,160.5 | 13,714.7 | 14,860.9 |
Trading (operating) profit, reported (ZAR Mn) | 2,896.9 | 3,650.4 | 3,623.0 | 4,171.9 | 4,678.5 |
Trading profit adjusted for 2021 civil unrest (ZAR Mn) | 3,045.0 | 3,325.0 | 3,623.0 | 4,171.9 | 4,678.5 |
Total depreciation and amortisation (ZAR Mn) | 1,260.4 | 1,374.6 | 1,519.0 | 1,742.3 | 1,882.0 |
EBITDA, derived (ZAR Mn) | 4,157.3 | 5,025.0 | 5,142.0 | 5,914.2 | 6,560.5 |
Net financing expense (ZAR Mn) | 186.1 | 164.8 | 139.4 | 265.2 | 243.0 |
Profit before tax, continuing (ZAR Mn) | 2,641.8 | 3,639.1 | 3,471.1 | 3,893.8 | 4,433.4 |
Income tax expense (ZAR Mn) | 727.7 | 1,000.5 | 933.6 | 1,056.8 | 1,197.1 |
Profit for the year, total (ZAR Mn) | 1,837.9 | 2,638.7 | 2,537.5 | 2,837.1 | 3,236.3 |
Headline earnings, total (ZAR Mn) | 1,911.5 | 2,522.9 | 2,542.9 | 2,844.6 | 3,234.3 |
Basic EPS (ZAR cents) | 743.8 | 1,080.1 | 1,042.3 | 1,190.3 | 1,362.6 |
Diluted EPS (ZAR cents) | 743.8 | 1,080.1 | 1,042.3 | 1,190.3 | 1,362.6 |
Diluted HEPS (ZAR cents) | 773.6 | 1,032.7 | 1,044.5 | 1,193.5 | 1,361.7 |
Dividend per share (ZAR cents) | 490 | 637 | 679 | 776 | 886 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 19.5 | 21.3 | 22.4 | 23.4 | 23.8 |
Total income margin (%) | 26.5 | 28.5 | 29.2 | 30.2 | 31.1 |
Trading margin, reported (%) | 7.8 | 9.2 | 8.7 | 9.2 | 9.8 |
Trading margin, unrest-adjusted (%) | 8.2 | 8.4 | 8.7 | 9.2 | 9.8 |
EBITDA margin, derived (%) | 11.1 | 12.7 | 12.4 | 13.0 | 13.7 |
Pre-tax margin, derived (%) | 7.1 | 9.2 | 8.3 | 8.6 | 9.3 |
Net margin, derived (%) | 4.9 | 6.7 | 6.1 | 6.2 | 6.8 |
Effective tax rate, derived (%) | 27.5 | 27.5 | 26.9 | 27.1 | 27.0 |
Turnover growth (%) | 10.2 | 6.0 | 5.1 | 9.2 | 5.3 |
Comparable-store turnover growth (%) | 5.1 | 8.4 | 3.5 | 8.4 | 4.3 |
Diluted HEPS growth (%) | 2.6 | 33.5 | 1.1 | 14.3 | 14.1 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (ZAR Mn) | 17,173.5 | 17,863.9 | 19,034.9 | 20,817.1 | 22,591.9 |
Cash and cash equivalents (ZAR Mn) | 2,206.6 | 2,014.6 | 2,455.2 | 2,705.0 | 3,255.8 |
Interest-bearing borrowings (ZAR Mn) | 0 | 0 | 0 | 0 | 0 |
Lease liabilities, current (ZAR Mn) | 947.0 | 1,012.2 | 1,086.4 | 1,249.6 | 1,334.2 |
Lease liabilities, non-current (ZAR Mn) | 1,975.9 | 2,087.7 | 2,152.5 | 2,536.7 | 2,708.3 |
Total lease liabilities (ZAR Mn) | 2,922.9 | 3,099.9 | 3,238.9 | 3,786.3 | 4,042.5 |
Net debt incl. leases, derived (ZAR Mn) | 716.3 | 1,085.3 | 783.7 | 1,081.3 | 786.7 |
Total equity (ZAR Mn) | 4,805.2 | 5,698.8 | 5,964.8 | 6,285.5 | 6,857.6 |
Goodwill (ZAR Mn) | 102.8 | 102.8 | 204.8 | 209.1 | 215.4 |
Intangible assets (ZAR Mn) | 670.5 | 721.0 | 968.2 | 946.4 | 941.6 |
Inventories (ZAR Mn) | 5,449.4 | 6,164.5 | 6,309.8 | 7,063.3 | 7,818.7 |
Trade and other receivables (ZAR Mn) | 3,473.1 | 3,047.0 | 3,019.5 | 3,057.3 | 3,139.5 |
Trade and other payables (ZAR Mn) | 8,751.6 | 8,368.7 | 9,268.9 | 10,030.9 | 10,912.5 |
Working capital, current assets less current liabilities (ZAR Mn) | 1,042.7 | 1,446.7 | 1,034.1 | 1,057.1 | 1,429.2 |
Net asset value per share (ZAR cents) | 1,957 | 2,336 | 2,473 | 2,640 | 2,907 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Cash generated by operations (ZAR Mn) | 4,559.0 | 4,278.1 | 5,863.6 | 6,001.2 | 6,606.5 |
Operating cash flow before dividends (ZAR Mn) | 3,780.6 | 3,204.0 | 4,872.9 | 4,682.1 | 5,241.2 |
Capex to maintain operations (ZAR Mn) | 217.4 | 337.6 | 356.5 | 337.0 | 311.8 |
Capex to expand operations (ZAR Mn) | 472.3 | 500.0 | 573.5 | 553.8 | 672.7 |
Total capex (ZAR Mn) | 689.7 | 837.6 | 930.0 | 890.9 | 984.5 |
Free cash flow before leases, derived (ZAR Mn) | 3,090.9 | 2,366.4 | 3,942.9 | 3,791.2 | 4,256.7 |
Lease liability repayments (ZAR Mn) | 786.9 | 879.5 | 955.0 | 1,007.7 | 1,066.1 |
Free cash flow after leases, derived (ZAR Mn) | 2,304.0 | 1,486.9 | 2,987.9 | 2,783.5 | 3,190.6 |
Dividends paid (ZAR Mn) | 1,468.9 | 1,286.9 | 1,562.8 | 1,676.0 | 1,911.3 |
Share buybacks (ZAR Mn) | 752.3 | 445.6 | 703.5 | 834.8 | 751.4 |
Total cash returned to shareholders (ZAR Mn) | 2,221.2 | 1,732.5 | 2,266.3 | 2,510.8 | 2,662.7 |
Acquisitions, net of cash acquired (ZAR Mn) | 6.0 | 0.0 | 241.0 | 7.4 | 7.0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Return on equity, company definition (%) | 38.2 | 48.0 | 43.6 | 46.4 | 49.2 |
Return on total assets, company definition (%) | 11.8 | 14.4 | 13.8 | 14.3 | 14.9 |
Current ratio (x) | 1.10 | 1.15 | 1.10 | 1.09 | 1.11 |
Lease liabilities to equity, derived (x) | 0.61 | 0.54 | 0.54 | 0.60 | 0.59 |
Net debt incl. leases to equity (%) | 14.9 | 19.0 | 13.1 | 17.2 | 11.5 |
Net debt incl. leases to EBITDA, derived (x) | 0.17 | 0.22 | 0.15 | 0.18 | 0.12 |
Interest cover, trading profit to financial expense, derived (x) | 13.2 | 17.4 | 15.6 | 11.8 | 12.3 |
Asset turnover, turnover to closing total assets, derived (x) | 2.17 | 2.22 | 2.19 | 2.18 | 2.12 |
Inventory days | 66 | 72 | 71 | 74 | 78 |
Trade debtor days | 38 | 27 | 34 | 31 | 29 |
Trade creditor days | 74 | 63 | 71 | 70 | 73 |
Net working capital days (cash conversion cycle) | 30 | 36 | 34 | 35 | 34 |
Returns & Leverage Ratios (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Return on invested capital, IFRS 16 basis (%) | 29.6 | 28.4 | 29.7 | 30.7 |
Returns & Leverage Ratios (%) (FY2023–FY2025)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Return on invested capital, excluding IFRS 16 (%) | 41.5 | 45.6 | 47.0 |
Cash Flow and Per-Share Data
| Metric | H1 FY2025 | H1 FY2026 |
|---|---|---|
Turnover (ZAR Mn) | 23,164.3 | 24,872.2 |
Gross profit (ZAR Mn) | 5,564.8 | 5,824.5 |
Total income (ZAR Mn) | 7,173.9 | 7,642.6 |
Trading profit (ZAR Mn) | 2,097.3 | 2,253.1 |
Profit before tax (ZAR Mn) | 1,968.9 | 2,090.5 |
Headline earnings (ZAR Mn) | 1,437.8 | 1,529.6 |
Diluted HEPS (ZAR cents) | 603.9 | 652.8 |
Interim DPS (ZAR cents) | 238 | 258 |
Capex (ZAR Mn) | 222.0 | 310.6 |
Return on equity, annualised (%) | 46.2 | 45.7 |
ROIC excluding IFRS 16 (%) | 43.2 | 48.2 |
Revenue by Region
| Metric | FY2024 | FY2025 |
|---|---|---|
UPD fine wholesale to Clicks (ZAR Mn) | 7,414.2 | 8,116.1 |
UPD fine wholesale to private hospitals (ZAR Mn) | 4,958.8 | 5,024.8 |
UPD fine wholesale to independent pharmacies and other (ZAR Mn) | 832.4 | 747.9 |
UPD bulk wholesale (ZAR Mn) | 4,544.2 | 4,769.3 |
Total distribution turnover (ZAR Mn) | 17,749.6 | 18,658.1 |
Retail turnover, all consumer channels (ZAR Mn) | 35,438.5 | 37,554.5 |
Revenue by Region (Half-Yearly)
| Metric | H1 FY2025 | H1 FY2026 |
|---|---|---|
UPD fine wholesale to Clicks (ZAR Mn) | 3,849.0 | 4,274.9 |
UPD fine wholesale to private hospitals (ZAR Mn) | 2,385.9 | 2,433.6 |
UPD fine wholesale to independent pharmacies and other (ZAR Mn) | 367.2 | 356.7 |
UPD bulk wholesale (ZAR Mn) | 2,169.1 | 2,842.8 |
Revenue by Region (%)
| Metric | FY2022 | FY2023 | FY2025 | H1 FY2026 |
|---|---|---|---|---|
Pharmacy share of retail sales (%) | 27.6 | 28.2 | 26.8 | 26.4 |
Vaccinations share of retail sales (%) | 3.9 | 0.0 | 0.0 | 0.0 |
Front shop health and baby share (%) | 25.8 | 25.4 | 25.6 | 24.7 |
Beauty and personal care share (%) | 28.3 | 31.0 | 32.5 | 33.8 |
General merchandise share (%) | 14.4 | 15.4 | 15.1 | 15.1 |
Share Price and Market Valuation
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Closing share price (ZAR) | 302.56 | 298.02 | 273.50 | 373.69 | 373.12 |
Share price high (ZAR) | 302.56 | 321.07 | 317.64 | 373.69 | 403.83 |
Share price low (ZAR) | 218.63 | 268.30 | 234.42 | 237.58 | 327.45 |
Market capitalisation (ZAR Bn) | 74.30 | 72.71 | 65.96 | 88.96 | 88.03 |
Price to diluted HEPS (x) | 39.1 | 28.9 | 26.2 | 31.3 | 27.4 |
Shares in issue (millions) | 245.557 | 243.970 | 241.161 | 238.062 | 235.931 |
Shares traded as % of weighted shares (%) | 87.8 | 83.4 | 76.0 | 84.8 | 82.0 |
Share Price History
| Date | Price / value | Source |
|---|---|---|
28 Feb 2026 | Close R318.21; market cap R74.4bn; P/E 26.1x | S2 |
2 Jan 2026 | R332.34 (about R77.7bn) | M1 |
22 Jan 2026 | R324.95 (down 6.2% on the day) | M4 |
23 Apr 2026 | About R275.88 (down more than 8% on the day) | M1 |
25 May 2026 | R248.11 (about R58bn) | M1 |
29 May 2026 | R234.50; down 27.7% YTD, 36.7% over 1 year, up 0.7% over 3 years | M6 |
23 Jun 2026 | R231.09; market cap R54.04bn; 52-week range R225.42–R389.21 | M7 |
13 Jul 2026 | Market cap R51.71bn; down 33.5% YTD | M2 |
21 Sep 2026 | Down 39% YTD; down 44.7% over 1 year | M3 |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Dividend per share (ZAR cents) | 272 | 322 | 380 | 445 | 450 | 490 | 637 | 679 | 776 | 886 |
Diluted HEPS (ZAR cents) | 439 | 502 | 575 | 664 | 754 | 774 | 1,033 | 1,045 | 1,194 | 1,362 |
Dividend payout ratio (%) | 59 | 60 | 62 | 65 | 60 | 63 | 62 | 65 | 65 | 65 |
Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Interim dividend (ZAR cents) | 142.5 | 180.0 | 185.0 | 210.0 | 238.0 |
Final dividend (ZAR cents) | 347.5 | 457.0 | 494.0 | 566.0 | 648.0 |
Analyst Conclusions
Management guidance
FY2026 diluted HEPS growth of 4–9%: Applied to FY2025 dHEPS of 1,361.7c, this implies roughly 1,416c to 1,484c (derived).
-
40–50 stores and 40–50 pharmacies.
-
10 concept-store pilots.
-
Capex of R1.26bn.
-
Continued commitment to the medium-term targets and the 1,200-store goal.
-
FY2026 results are expected in late October 2026 (not confirmed).
Consensus growth expectations
Aggregators showed consensus revenue growth of about 7.8% a year as of mid-2026 (Simply Wall St). Detailed broker consensus EPS was not available in sources reviewed.
Bull case
-
The derating looks like an over-correction for a business that still meets every return target. The P/E roughly halved, from 31.3x at the FY2024 year-end to about 16–17x at June 2026 prices. Yet H1 FY2026 ROIC excluding IFRS 16 rose to 48.2%, and retail trading profit grew 11%.
-
The H1 problems were largely one-off and are now fixed. WMS availability normalised by end-February. The R175m lost-sales base effect and the Unicorn-distorted margin comparison both drop out in FY2027. Meanwhile pharmacy share hit a record 24.9%.
-
Capital returns compound at depressed prices. No bank debt, post-lease free cash flow of R3.2bn (FY2025, derived) and a 65% payout leave room for continued buybacks at much lower prices than in FY2025.
Bear case
-
Competition is structural, not cyclical. Dis-Chem's Better Rewards and wholesale push (external wholesale +13.7%) and Shoprite's Medirite Plus (+73.5%) hit both of Clicks' engines at once. Front-shop and skincare share both fell in H1 FY2026 (S2, M3, M5).
-
UPD is shrinking in its non-captive channels. Managed turnover fell 0.2% in H1 FY2026. Wholesale share fell to 25.7%, two principals were lost, and the 2026 SEP increase is capped at 1.47%. Distribution's earnings contribution is under pressure.
-
Margin-led growth has run its course. The gross margin is already 23.8% and the total income margin fell in H1 FY2026. Without volume (0.8% in H1 FY2026) or inflation (2.0% internal selling-price inflation), earnings growth likely settles in mid-single digits.
Key catalysts and monitorables (next 12 months)
-
FY2026 results (expected late October 2026): delivery within the 4–9% range; quality of the H2 trading margin; FY2027 capex and store targets.
-
January 2027 festive trading update: comparable-store growth against a weak base; promotional intensity.
-
ClubCard changes (monthly cashback, personalisation) against Dis-Chem Better Rewards: membership and sales-share trend.
-
Inventory days returning toward 78 or below; WMS rollout to the Durban DC without disruption.
-
Pharmacy licence flow (105 stores without a dispensary) and the UniCare rollout pace.
-
UPD: new bulk contracts; the medical consumables ramp-up; the 2027 SEP decision.
-
Buyback pace and any change to the 60–65% payout policy.
-
Shoprite Medirite Plus expansion and Spar/Aptekor wholesale traction.
Analyst verdict
Clicks Group enters FY2027 with its franchise intact but its narrative broken. Operationally, the evidence does not support a thesis of decline. Pharmacy market share reached a record 24.9%. Retail trading profit grew 11% in H1 FY2026. ROIC excluding IFRS 16 is 48%. The balance sheet carries no bank debt and generates about R3bn a year of post-lease free cash flow. Few South African retailers can match any of those metrics, let alone all of them.
What has changed is the growth algorithm that justified a 30x multiple. For a decade, Clicks turned mid-single-digit sales growth into low-to-mid-teens earnings growth through mix, private label and supplier income. That conversion now appears close to exhausted. The total-income margin fell in H1 FY2026, volumes are barely positive, inflation is about 2%, and management guides only 4–9% dHEPS growth. At the same time, two credible, well-capitalised competitors are attacking simultaneously: Dis-Chem through loyalty and wholesale, and Shoprite through Medirite Plus and Transpharm. UPD's non-captive channels and principal contracts are eroding. The festive-season WMS failure, though now remedied, damaged confidence in execution at the worst possible moment.
At roughly 16–17x trailing earnings and about 8x IFRS 16 EV/EBITDA (derived at the June 2026 reference price), the market now prices Clicks as a mid-single-digit grower. That is close to fair if the bear case holds, and attractive if store growth, UniCare, private label and buybacks restore high-single-digit to low-double-digit per-share growth from FY2027. The asymmetry has improved materially. The burden of proof now lies with management to show stable front-shop shares, normalised working capital and a competitive ClubCard response in the FY2026 results and the January 2027 update.
On balance, the stock's risk-reward appears to have shifted from expensive-quality to quality-at-a-reasonable-price. Conviction should be calibrated to evidence of share stabilisation rather than to the historical return record alone.
End of dossier. All forward-looking statements reflect company guidance or analyst interpretation as of 13 October 2026.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / appointment | Background (as disclosed) | Age (where disclosed) |
|---|---|---|---|---|
Mfundiso (JJ) Njeke | Independent non-executive chairman | Board since 2020; chairman since 30 Jan 2025 | Chartered accountant; co-founder and former group MD of Kagiso Trust Investments; past chairman of SAICA; chairman of Motus Holdings; NED of Datatec | 65 (Aug 2024) |
Bertina Engelbrecht | Chief executive officer | Joined 2006 as group HR director; executive director since 2008; CEO since 1 Jan 2022 | B.Proc, LLM; admitted attorney; previously group corporate affairs director | 58 (Sep 2021) |
Gordon Traill | Chief financial officer | Appointed 1 Jan 2023 | Chartered accountant; British national. | — |
Sango Ntsaluba | Independent NED; lead independent director since 30 Jan 2025; remuneration committee chair | Appointed 1 Sep 2021 | Chartered accountant; more than 30 years in audit and corporate leadership | — |
Nomgando Matyumza | Independent NED; audit & risk committee member | Appointed 1 Sep 2022 | Chartered accountant; B Com, B Compt (Hons), LLB; NED of Standard Bank Group, Sasol and VW SA | 59 (Aug 2022) |
Christine Ramon | Independent NED; remuneration committee member | Appointed 7 Feb 2023 | Chartered accountant; former CFO of AngloGold Ashanti (8 years, incl. 1 year as interim CEO) and of Sasol (7 years); NED of Vodafone plc | — |
Richard Inskip | Independent NED; remuneration committee member | Appointed 1 Jul 2023 | Not detailed in sources reviewed | — |
Penelope (PM) Osiris (née Moumakwa) | Independent NED; also director of New Clicks South Africa (Pty) Ltd | — | Not detailed in sources reviewed | — |
Bertie van Sittert | Independent NED | Appointed 1 Feb 2026 | Chartered accountant; former PwC associate director; six years at Clicks incl. head of finance for Clicks; MBA (cum laude) from Stellenbosch; about a decade as chief executive: finance of Pep Stores (Pepkor) | 50 (Oct 2025) |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Title |
|---|---|
Bertina Engelbrecht | CEO |
Gordon Traill | CFO |
Bongiwe Ntuli | Managing executive: Clicks Retailers |
Bridget Makhura | Chief people officer |
Dhevan Pillay | Managing executive: Retail Business Development |
Gwarega Mangozhe | Managing executive: Africa |
Trevor McCoy | Managing executive: UPD |
Directors' Remuneration
| Metric | FY2024 | FY2025 |
|---|---|---|
CEO salary (ZAR K) | 10,223 | 11,143 |
CEO pension (ZAR K) | 653 | 711 |
CEO short-term incentive (ZAR K) | 6,573 | 8,891 |
CEO long-term incentive vesting (ZAR K) | 15,654 | 10,133 |
CEO total remuneration (ZAR K) | 33,103 | 30,878 |
CFO salary (ZAR K) | 5,984 | 6,627 |
CFO pension (ZAR K) | 789 | 873 |
CFO short-term incentive (ZAR K) | 3,411 | 4,500 |
CFO long-term incentive vesting (ZAR K) | 3,594 | 5,072 |
CFO total remuneration (ZAR K) | 13,778 | 17,072 |
Non-executive directors' fees, total (ZAR K) | 7,083 | 7,114 |
Board & Management Changes
| Date | Change |
|---|---|
23 Sep 2021 | CEO Vikesh Ramsunder resigns (effective 31 Dec 2021) to lead a listed Australian company; Bertina Engelbrecht named CEO from 1 Jan 2022 |
1 Jan 2023 | Gordon Traill appointed CFO |
1 Feb 2024 | John Bester retires as NED; Njeke becomes lead independent director |
31 Oct 2024 | Annalize Barnard becomes company secretary |
30 Jan 2025 | David Nurek retires; JJ Njeke becomes chairman; Ntsaluba becomes lead independent director |
FY2025 | Vikash Singh (managing executive, Total Health & Beauty) resigns; group executive restructured |
1 Feb 2026 | Bertie van Sittert joins the board |
Shareholding Trend
| Holder | Feb 2025 (%) | Feb 2026 (%) |
|---|---|---|
Public Investment Corporation (SA) | 17.8 | 18.2 |
BlackRock (US and UK) | 5.2 | 5.6 |
GIC (Singapore) | 4.5 | 4.8 |
The Vanguard Group (US) | 4.0 | 4.2 |
RBC Global Asset Management (UK and US) | 3.4 | 4.1 |
Lazard Asset Management (US and UK) | 1.4 | 3.4 |
JPMorgan Asset Management (US and UK) | 3.8 | 3.4 |
Ninety One Asset Management (SA), below 3% | 4.8 | 0.3 |
Competitive Landscape
Key Competitors
| Competitor | Segment(s) | Key metrics (as disclosed) | Positioning vs Clicks |
|---|---|---|---|
Dis-Chem Pharmacies (JSE: DCP) | Retail pharmacy, front shop, baby, wholesale, primary care, insurance | FY2026 (Feb): revenue R42.8bn (+9.3%); retail R36.6bn (+9.0%); wholesale R34.0bn (+13.1%, incl. own stores); profit R1.04bn (-15.1%); basic EPS 114.2c (-17.1%); adjusted PBT R1.8bn (+20.1%); 316 pharmacies plus 42 Baby City stores (M5) | Larger stores; claims the largest dispensary market share (Feb 2025 trading update); Better Rewards with Capitec; vertically integrating into care and insurance |
Shoprite – Medirite / Medirite Plus / Transpharm (JSE: SHP) | Retail pharmacy (in-supermarket counters and standalone); wholesale | About 122 in-store Medirite counters plus 18 Medirite Plus standalone (H1 FY2026); Medirite sales +13.5% and Medirite Plus +73.5% (FY2026); Transpharm sales +5.5% (M3, M15) | Scale, footfall and data; group valued at R186bn with 2,747 stores (M3) |
Spar – Pharmacy at Spar / Aptekor (JSE: SPP) | Retail pharmacy; wholesale | About 125 pharmacies (M12); entered pharma wholesale via Aptekor (M8) | Emerging wholesale rival |
Alpha Pharm (independent network) | Retail pharmacy | 350+ pharmacies (M12) | Independent buying group; UPD customer and competitor channel |
Link Pharmacy (independent network) | Retail pharmacy | 300+ pharmacies (M12) | UPD relaunched its offer to Link |
The Local Choice (Dis-Chem franchise) | Retail pharmacy franchise; Dis-Chem wholesale customer | TLC revenue +14.2% (Dis-Chem trading update, Feb 2026) | Shifts independents' purchasing away from UPD |
Independent pharmacies (various) | Retail pharmacy | Clicks retail share of 24.9% implies independents and others hold the majority of the market | Consolidating |
Pick n Pay (JSE: PIK) | Front-shop health and beauty in grocery | Exited pharmacy in 2021, selling 25 dispensaries to Clicks | Health and beauty aisle competitor |
Online platforms (e.g. Takealot; Checkers Sixty60) | Online beauty, personal care, OTC | Not disclosed for these categories | Clicks' own risk register lists global online retailers as a disruption risk |
Salon chains and independent salons | Beauty services (vs Sorbet) | — | Fragmented |
Other pharmaceutical wholesalers | Pharma wholesale and logistics | Market shares not disclosed in sources reviewed | UPD wholesale share fell from 31.1% (FY2021) to 25.7% (Feb 2026) on an IQVIA basis, with restatements |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | Clicks Group (FY Aug 2025) | Dis-Chem (FY Feb 2026) | Shoprite – Medirite (FY Jun 2026) |
|---|---|---|---|
Group revenue / turnover (ZAR Bn) | 47.8 | 42.8 | — |
Revenue growth (%) | 5.3 | 9.3 | Medirite sales +13.5 |
Retail revenue (ZAR Bn) | 37.6 | 36.6 | — |
Retail growth (%) | 6.0 | 9.0 | Medirite Plus pharmacy +73.5 |
Net profit (ZAR Bn) | 3.24 | 1.04 | — |
Net margin, derived (%) | 6.8 | 2.4 | — |
Pharmacies (number) | 780 (797 at Feb 2026) | 316 | about 140 counters and standalone |
Loyalty programme | ClubCard, 12.6m active | Better Rewards (Capitec-linked) | Xtra Savings (group) |
“—” = not publicly disclosed.
Recent Developments
Litigation, regulatory actions or layoffs in the 18-month window:* none identified in sources reviewed.



